Covered recipient · General Payments record
JEFFREY D MILES
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neuromuscular Medicine
General Payments · PY2018–2024
$13,091.77
- Reported across 86 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,940.00 | 1 |
| Food and Beverage | $854.40 | 32 |
| Education | $95.50 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $3,153.57 | 6 |
| ABBVIE INC. | $259.80 | 12 |
| UCB, Inc. | $234.24 | 9 |
| Teva Pharmaceuticals USA, Inc. | $115.25 | 2 |
| ARGENX US, INC. | $73.34 | 3 |
| Alnylam Pharmaceuticals Inc. | $28.16 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $25.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.25 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034505 | CMS |
| ABBVIE INC. | $32.21 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034507 | CMS |
| ABBVIE INC. | $33.65 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034509 | CMS |
| ABBVIE INC. | $11.31 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034511 | CMS |
| ABBVIE INC. | $18.06 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034513 | CMS |
| ABBVIE INC. | $15.33 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034515 | CMS |
| ABBVIE INC. | $33.56 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034517 | CMS |
| ABBVIE INC. | $12.16 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034519 | CMS |
| ABBVIE INC. | $16.23 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034521 | CMS |
| ABBVIE INC. | $15.80 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034523 | CMS |
| ABBVIE INC. | $26.85 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034525 | CMS |
| ABBVIE INC. | $27.39 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105034527 | CMS |
| Alexion Pharmaceuticals, Inc. | $15.49 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094016104 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.14 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093927508 | CMS |
| Alexion Pharmaceuticals, Inc. | $24.52 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093892541 | CMS |
| Alexion Pharmaceuticals, Inc. | $25.29 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093991176 | CMS |
| Alexion Pharmaceuticals, Inc. | $131.13 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093912773 | CMS |
| Alexion Pharmaceuticals, Inc. | $2,940.00 | 11/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1094030235 | CMS |
| Alnylam Pharmaceuticals Inc. | $28.16 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125835431 | CMS |
| ARGENX US, INC. | $32.18 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142112417 | CMS |
| ARGENX US, INC. | $23.23 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142109143 | CMS |
| ARGENX US, INC. | $17.93 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142110835 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $25.54 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137635868 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.75 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151689483 | CMS |
| Teva Pharmaceuticals USA, Inc. | $95.50 | 06/11/2024 | Education | Undisputed | 01/23/2026 | 1151689498 | CMS |
| UCB, Inc. | $2.20 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362178 | CMS |
| UCB, Inc. | $22.01 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362182 | CMS |
| UCB, Inc. | $29.39 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362187 | CMS |
| UCB, Inc. | $2.00 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362191 | CMS |
| UCB, Inc. | $48.79 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362195 | CMS |
| UCB, Inc. | $1.66 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362200 | CMS |
| UCB, Inc. | $26.98 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362204 | CMS |
| UCB, Inc. | $76.49 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362209 | CMS |
| UCB, Inc. | $24.72 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143362213 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.